Michael A. Schwarzschild, MD, PhD, is a neurologist at Massachusetts General Hospital and professor of neurology at Harvard Medical School. Dr. Schwarzschild’s research investigates genetic and environmental factors linked to Parkinson’s disease (PD) and translates insights gained from preclinical laboratory models to clinical trials. His group discovered the neuroprotective properties of caffeine and other adenosine A2A receptor blockers in mouse models of PD. Since 2012, he has led the Parkinson Study Group (PSG), a network of North American clinical trialists dedicated to improving therapy for people with PD.